Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

A Matchmaker for Patients Seeking Clinical Trials
In the past day, I’ve had several rare and common diseases, including some horrendous stuff, but all in the name of science. My sudden… Continue Reading
Right-to-Try Bill Fails in the House
Rare Daily Staff Legislation intended to give patients easier access to experimental therapies without needing to go through the U.S. Food… Continue Reading
VIDEO: How I Learned to See through the Eyes of my Sons
Kristin Smedley, president of Curing Retinal Blindness Foundation, discusses her feelings of devestation when she learned her newborn son… Continue Reading
Sanofi Passes on Alnylam Primary Hyperoxaluria Type 1 Candidate
Rare Daily Staff Alnylam Pharmaceuticals said that Sanofi Genzyme has opted out of its rights to develop and commercialize Lumasiran,… Continue Reading
Sarepta Therapeutics Plans to Submit DMD Drug Golodirsen for FDA Approval by Year End
Rare Daily Staff Sarepta Therapeutics said that following its meeting with The U.S. Food and Drug Administration about the development… Continue Reading
Addressing the Challenges of Rare Disease Drug Development
Developing therapeutics for rare diseases can be challenging, and not just because of the small patient populations. Often the progression… Continue Reading
The Global Genes Rare Disease Stock Index Ends Week Up 6.38 Percent on Strong Jobs Report
A stronger than expected jobs report pushed markets higher despite concerns that new U.S. tariffs on steel and aluminum could trigger a… Continue Reading